Seattle Genetics Issue Update on Padcev Label Expansion Study

Seattle Genetics, Inc. SGEN announced an update on the phase Ib/II EV-103 study evaluating Padcev (enfortumab vedotin-ejfv) in combination with Merck’s MRK PD-1/L1 inhibitor Keytruda (pembrolizumab) for addressing patients with unresectable locally advanced/metastatic urothelial cancer who are not able to receive cisplatin-based chemotherapy in the first-line setting.